{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:34:02Z","timestamp":1785548042884,"version":"3.56.0"},"reference-count":111,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T00:00:00Z","timestamp":1677369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073419"],"award-info":[{"award-number":["82073419"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), a chronic condition associated with metabolic dysfunction and obesity, has reached epidemic proportions worldwide. Although early NAFLD can be treated with lifestyle changes, the treatment of advanced liver pathology, such as nonalcoholic steatohepatitis (NASH), remains a challenge. There are currently no FDA-approved drugs for NAFLD. Fibroblast growth factors (FGFs) play essential roles in lipid and carbohydrate metabolism and have recently emerged as promising therapeutic agents for metabolic diseases. Among them, endocrine members (FGF19 and FGF21) and classical members (FGF1 and FGF4) are key regulators of energy metabolism. FGF-based therapies have shown therapeutic benefits in patients with NAFLD, and substantial progress has recently been made in clinical trials. These FGF analogs are effective in alleviating steatosis, liver inflammation, and fibrosis. In this review, we describe the biology of four metabolism-related FGFs (FGF19, FGF21, FGF1, and FGF4) and their basic action mechanisms, and then summarize recent advances in the biopharmaceutical development of FGF-based therapies for patients with NAFLD.<\/jats:p>","DOI":"10.3390\/ijms24054583","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T03:29:48Z","timestamp":1677468588000},"page":"4583","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges"],"prefix":"10.3390","volume":"24","author":[{"given":"Haoyu","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuairan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China"},{"name":"Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7063-7742","authenticated-orcid":false,"given":"Dianbao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Golabi, P., Paik, J.M., Henry, A., Van Dongen, C., and Henry, L. (Hepatology, 2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review, Hepatology, ahead of print.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yip, T.C., Vilar-Gomez, E., Petta, S., Yilmaz, Y., Wong, G.L., Adams, L.A., de L\u00e9dinghen, V., Sookoian, S., and Wong, V.W. (Hepatology, 2022). Geographical similarity and differences in the burden and genetic predisposition of NAFLD, Hepatology, ahead of print.","DOI":"10.1002\/hep.32774"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000333210","article-title":"Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area","volume":"84","author":"Cho","year":"2011","journal-title":"Digestion"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.freeradbiomed.2021.06.024","article-title":"Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study","volume":"172","author":"Mazi","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: Leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: A population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_10","first-page":"83","article-title":"Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"15","author":"Wong","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","article-title":"Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease","volume":"153","author":"VanWagner","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic Fatty Liver Disease: A Systematic Review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.12968\/hmed.2018.79.12.694","article-title":"The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis","volume":"79","author":"Day","year":"2018","journal-title":"Br. J. Hosp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: An Overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vancells Lujan, P., Vi\u00f1as Esmel, E., and Sacanella Meseguer, E. (2021). Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients, 13.","DOI":"10.3390\/nu13051442"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-med-042220-020407","article-title":"Fatty Liver Disease: Diagnosis and Stratification","volume":"73","author":"Saiman","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.mayocp.2022.04.005","article-title":"Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers","volume":"97","author":"Basu","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Nasr","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.27720","article-title":"Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014","volume":"62","author":"Torok","year":"2015","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: Clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving Role for Pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Onakpoya, I.J., Heneghan, C.J., and Aronson, J.K. (2016). Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: A systematic review. BMC Med., 14.","DOI":"10.1186\/s12916-016-0735-y"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"603926","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Smeuninx, B., Boslem, E., and Febbraio, M.A. (2020). Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. Cancers, 12.","DOI":"10.3390\/cancers12071714"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: Biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1242\/dev.152587","article-title":"Fibroblast growth factors: Key players in regeneration and tissue repair","volume":"144","author":"Maddaluno","year":"2017","journal-title":"Development"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-010-1024-2","article-title":"Hormone-like (endocrine) Fgfs: Their evolutionary history and roles in development, metabolism, and disease","volume":"342","author":"Itoh","year":"2010","journal-title":"Cell Tissue Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cmet.2021.12.004","article-title":"FGF1 and insulin control lipolysis by convergent pathways","volume":"34","author":"Sancar","year":"2022","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1038\/s41467-021-27584-y","article-title":"Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects","volume":"12","author":"Ying","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: Fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: From biological function to clinical application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1074\/jbc.M110.116004","article-title":"Regulation of bile acid synthesis by fat-soluble vitamins A and D","volume":"285","author":"Schmidt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1194\/jlr.M012781","article-title":"A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB\/NJ mice","volume":"52","author":"Henkel","year":"2011","journal-title":"Journal of lipid research"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1194\/jlr.M027094","article-title":"Dual actions of fibroblast growth factor 19 on lipid metabolism","volume":"54","author":"Wu","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/liv.14802","article-title":"Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease","volume":"41","author":"Sciarrillo","year":"2021","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/00365510701854967","article-title":"Fibroblast growth factor-19: Development, analytical characterization and clinical evaluation of a new ELISA test","volume":"68","author":"Stejskal","year":"2008","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Alisi, A., Ceccarelli, S., Panera, N., Prono, F., Petrini, S., De Stefanis, C., Pezzullo, M., Tozzi, A., Villani, A., and Bedogni, G. (2013). Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067160"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1073\/pnas.1009427107","article-title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)","volume":"107","author":"Wu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1074\/jbc.M110.215889","article-title":"Thermogenic activation induces FGF21 expression and release in brown adipose tissue","volume":"286","author":"Hondares","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"\u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1&#x3b1; and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"ref_71","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wong, C., Dash, A., Fredrickson, J., Lewin-Koh, N., Chen, S., Yoshida, K., Liu, Y., Gutierrez, J., and Kunder, R. (Hepatology, 2022). Fibroblast growth factor receptor 1\/Klotho\u03b2 agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial, Hepatology, ahead of print.","DOI":"10.1002\/hep.32742"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Weng, Y., Chabot, J.R., Bernardo, B., Yan, Q., Zhu, Y., Brenner, M.B., Vage, C., Logan, A., Calle, R., and Talukdar, S. (2015). Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK\/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119104"},{"key":"ref_76","first-page":"427","article-title":"Expression of acidic fibroblast growth factor in regenerating liver and during hepatic differentiation","volume":"67","author":"Marsden","year":"1992","journal-title":"Lab. Investig. A J. Tech. Methods Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1073\/pnas.1525093113","article-title":"Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fphar.2020.00052","article-title":"Fibroblast Growth Factor 1 Ameliorates Diabetes-Induced Liver Injury by Reducing Cellular Stress and Restoring Autophagy","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1677\/erc.1.00535","article-title":"The role of fibroblast growth factors and their receptors in prostate cancer","volume":"11","author":"Ozen","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s10517-009-0710-0","article-title":"Endostatin, placental growth factor, and fibroblast growth factors-1 and -2 in the sera of patients with primary osteosarcomas","volume":"148","author":"Babkina","year":"2009","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Bookout","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"747245","DOI":"10.1155\/2015\/747245","article-title":"Mesenchymal Stem Cells Pretreated with HGF and FGF4 Can Reduce Liver Fibrosis in Mice","volume":"2015","author":"Shams","year":"2015","journal-title":"Stem Cells Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol. Carcinog."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/sj.onc.1207348","article-title":"HST-1\/FGF-4 plays a critical role in crypt cell survival and facilitates epithelial cell restitution and proliferation","volume":"23","author":"Sasaki","year":"2004","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.32404","article-title":"FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis","volume":"76","author":"Song","year":"2022","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"166560","DOI":"10.1016\/j.bbadis.2022.166560","article-title":"A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway","volume":"1868","author":"Wang","year":"2022","journal-title":"Biochim. Et Biophys. Acta Mol. Basis Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1248\/bpb.b14-00276","article-title":"Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice","volume":"38","author":"Masuda","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","article-title":"In situ click chemistry generation of cyclooxygenase-2 inhibitors","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14728222.2021.1999416","article-title":"A short report on NGM282\/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"25","author":"Roberts","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Kharitonenkov, A., Beals, J.M., Micanovic, R., Strifler, B.A., Rathnachalam, R., Wroblewski, V.J., Li, S., Koester, A., Ford, A.M., and Coskun, T. (2013). Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058575"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Adams, A.C., Halstead, C.A., Hansen, B.C., Irizarry, A.R., Martin, J.A., Myers, S.R., Reynolds, V.L., Smith, H.W., Wroblewski, V.J., and Kharitonenkov, A. (2013). LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065763"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/jpet.113.204420","article-title":"Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody","volume":"346","author":"Huang","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): An investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_101","unstructured":"Krupinski, J., Morgan, N., Kozhich, A., Chiney, M., Morin, P., and Christian, R. (2016). Hepatology, Wiley."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward \u03b2-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.1880050311","article-title":"Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis","volume":"5","author":"Longo","year":"1995","journal-title":"J. Magn. Reson. Imaging JMRI"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4583\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:43:15Z","timestamp":1760121795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,26]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24054583"],"URL":"https:\/\/doi.org\/10.3390\/ijms24054583","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,26]]}}}